4 citations
,
May 2025 in “Dermatology and Therapy” This study found that baricitinib improved symptoms of atopic dermatitis and alopecia areata in both adults and children in real-world settings, aligning with clinical trial results, while noting low discontinuation due to adverse events and no new safety concerns.
6 citations
,
February 2023 in “Advances in Therapy” This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.
March 2025 in “Journal of the European Academy of Dermatology and Venereology” In a retrospective multicenter cohort study, this research observed that baricitinib was effective and well-tolerated in treating adult patients with alopecia areata, including those with severe cases, showing promise in improving outcomes over a 12-month period with manageable side effects.
January 2025 in “Frontiers in Pediatrics” This case report describes a child with alopecia areata and atopic dermatitis who showed significant improvement after treatment with baricitinib and corticosteroid ointment, suggesting their potential efficacy and safety.
June 2022 in “Value in Health” This study estimates that adding baricitinib to a commercial formulary for treating severe alopecia areata would slightly increase the budget by $1,383,345 over five years, with minimal impact per member per month.
